Annexon (ANNX) Competitors $1.54 +0.01 (+0.65%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$1.56 +0.01 (+0.97%) As of 04/15/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANNX vs. GYRE, DAWN, AVXL, PHVS, XERS, NTLA, EOLS, AVDL, CRON, and PRAXShould you be buying Annexon stock or one of its competitors? The main competitors of Annexon include Gyre Therapeutics (GYRE), Day One Biopharmaceuticals (DAWN), Anavex Life Sciences (AVXL), Pharvaris (PHVS), Xeris Biopharma (XERS), Intellia Therapeutics (NTLA), Evolus (EOLS), Avadel Pharmaceuticals (AVDL), Cronos Group (CRON), and Praxis Precision Medicines (PRAX). These companies are all part of the "pharmaceutical products" industry. Annexon vs. Gyre Therapeutics Day One Biopharmaceuticals Anavex Life Sciences Pharvaris Xeris Biopharma Intellia Therapeutics Evolus Avadel Pharmaceuticals Cronos Group Praxis Precision Medicines Gyre Therapeutics (NASDAQ:GYRE) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, community ranking, media sentiment and dividends. Do analysts prefer GYRE or ANNX? Annexon has a consensus price target of $18.67, suggesting a potential upside of 1,112.12%. Given Annexon's higher probable upside, analysts clearly believe Annexon is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Annexon 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, GYRE or ANNX? Gyre Therapeutics has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500. Comparatively, Annexon has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Does the MarketBeat Community favor GYRE or ANNX? Annexon received 54 more outperform votes than Gyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Gyre Therapeutics an outperform vote while only 77.46% of users gave Annexon an outperform vote. CompanyUnderperformOutperformGyre TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesAnnexonOutperform Votes5577.46% Underperform Votes1622.54% Do institutionals and insiders believe in GYRE or ANNX? 24.0% of Gyre Therapeutics shares are held by institutional investors. 19.5% of Gyre Therapeutics shares are held by company insiders. Comparatively, 12.7% of Annexon shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media favor GYRE or ANNX? In the previous week, Gyre Therapeutics had 1 more articles in the media than Annexon. MarketBeat recorded 5 mentions for Gyre Therapeutics and 4 mentions for Annexon. Annexon's average media sentiment score of 1.16 beat Gyre Therapeutics' score of 0.20 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Annexon 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is GYRE or ANNX more profitable? Annexon has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -84.57%. Annexon's return on equity of -38.99% beat Gyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gyre Therapeutics-84.57% -118.43% -71.97% Annexon N/A -38.99%-33.90% Which has stronger valuation and earnings, GYRE or ANNX? Gyre Therapeutics has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGyre Therapeutics$105.76M7.44-$92.93M$0.05168.00AnnexonN/AN/A-$134.24M-$1.02-1.51 SummaryGyre Therapeutics beats Annexon on 9 of the 16 factors compared between the two stocks. Remove Ads Get Annexon News Delivered to You Automatically Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANNX vs. The Competition Export to ExcelMetricAnnexonPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$168.95M$6.32B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.33%P/E Ratio-1.476.7921.7317.81Price / SalesN/A225.93379.1494.58Price / CashN/A65.6738.1534.64Price / Book0.485.866.464.00Net Income-$134.24M$141.86M$3.20B$247.23M7 Day PerformanceN/A8.98%6.54%7.26%1 Month Performance-40.77%-12.65%-8.55%-6.26%1 Year Performance-73.17%-11.99%10.33%-0.18% Annexon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANNXAnnexon2.7493 of 5 stars$1.54+0.7%$18.67+1,112.1%-73.2%$168.95MN/A-1.4760Short Interest ↓News CoverageGap DownGYREGyre Therapeutics0.1333 of 5 stars$7.62+10.1%N/A-49.0%$713.32M$105.76M152.4040Short Interest ↑High Trading VolumeDAWNDay One Biopharmaceuticals2.4554 of 5 stars$7.02-2.8%$32.29+359.9%-48.1%$711.51M$131.16M-6.8260Gap DownAVXLAnavex Life Sciences3.5111 of 5 stars$8.33+1.7%$44.00+428.2%+115.6%$708.58MN/A-15.1540Gap DownPHVSPharvaris1.4049 of 5 stars$13.21-7.5%$40.50+206.6%-30.8%$690.75MN/A-4.7230Gap UpXERSXeris Biopharma4.319 of 5 stars$4.41flat$6.10+38.3%+136.8%$678.88M$203.07M-9.80290Short Interest ↑News CoveragePositive NewsNTLAIntellia Therapeutics4.3276 of 5 stars$6.54-1.4%$37.56+474.2%-67.9%$677.00M$57.88M-1.20600High Trading VolumeEOLSEvolus3.5092 of 5 stars$10.24-4.2%$24.67+140.9%-14.0%$651.13M$266.27M-11.25170Analyst RevisionPositive NewsGap DownAVDLAvadel Pharmaceuticals2.2544 of 5 stars$6.69-1.6%$19.88+197.1%N/A$646.45M$169.12M-8.4770Analyst RevisionGap DownCRONCronos Group1.5759 of 5 stars$1.68-1.8%$3.00+78.6%-29.5%$642.65M$117.62M-12.92450PRAXPraxis Precision Medicines2.9287 of 5 stars$31.53-3.4%$123.33+291.2%-44.4%$635.74M$8.55M-3.06110 Remove Ads Related Companies and Tools Related Companies GYRE Competitors DAWN Competitors AVXL Competitors PHVS Competitors XERS Competitors NTLA Competitors EOLS Competitors AVDL Competitors CRON Competitors PRAX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANNX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annexon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ANNX Stock Free ANNX Stock Alerts